Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 13, 2018. The report details the vesting of conditional share awards and the subsequent sale or withholding of shares to meet tax liabilities for Persons Discharging Managerial Responsibility (PDMRs) under the 2015 GlaxoSmithKline Share Value Plan (SVP).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports specific transaction volumes and prices related to executive compensation:
- Instrument: Ordinary Shares of 25 pence each (ISIN: GB0009252882).
- Transaction Date: February 12, 2018.
- Exchange: London Stock Exchange (XLON).
Material Changes and Transaction Details
The filing reports the following specific transactions executed on February 12, 2018:
- Mr. L. Debruyne (President, Global Vaccines): Vesting and release of 6,433 Ordinary Shares. No sale price is listed as this was a vesting event.
- Mrs. V. A. Whyte (Company Secretary):
- Vesting and release of 11,060 Ordinary Shares.
- Sale of 5,199 Ordinary Shares to meet tax liabilities at a price of £12.9521 per share.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business performance, risks, contingencies, or unusual items. The document is strictly a regulatory notification of insider share transactions.
Investor Verification Checklist
- Verify the total number of shares vested versus shares sold to meet tax obligations for the named executives.
- Confirm the share price of £12.9521 against the market price on the London Stock Exchange for February 12, 2018.
- Review the full 2015 Share Value Plan terms to understand the vesting conditions that were met.
- Note that this filing contains no data on the company's operational or financial performance for the period.